TY - JOUR
T1 - Multiple Protective Roles of Nanoliposome-Incorporated Baicalein against Alpha-Synuclein Aggregates
AU - Aliakbari, Farhang
AU - Mohammad-Beigi, Hossein
AU - Abbasi, Shahsanam
AU - Rezaei-Ghaleh, Nasrollah
AU - Lermyte, Frederik
AU - Parsafar, Soha
AU - Becker, Stefan
AU - Tafreshi, Azita Parvaneh
AU - O'Connor, Peter B.
AU - Collingwood, Joanna F.
AU - Christiansen, Gunna
AU - Sutherland, Duncan S.
AU - Jensen, Poul Henning
AU - Morshedi, Dina
AU - Otzen, Daniel E.
N1 - Publisher Copyright:
© 2020 The Authors. Advanced Functional Materials published by Wiley-VCH GmbH
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/2/10
Y1 - 2021/2/10
N2 - Nanoparticles are useful for increasing drug stability, solubility, and availability. The small molecule baicalein inhibits fibrillation, and detoxifies aggregates of α-synuclein (αSN) associated with Parkinson's disease (PD), but it suffers from instability, low solubility and consequent low availability. Here it is demonstrated that incorporation of baicalein into zwitterionic nanoliposomes (NLP-Ba) addresses these problems. NLP-Ba inhibits αSN fibril initiation, elongation, secondary nucleation, and also depolymerizes mature fibrils more effectively than free baicalein and prevents soluble αSN aggregates from seeding new fibrils. Importantly, NLP-Ba perturbs oligomers’ capacity to permeabilize the membrane. The interaction between NLP-Ba and αSN is confirmed by different biophysical techniques. This nanosystem crosses the blood-brain barrier in vitro and is effective against rotenone neurotoxicity in vivo. The effect of NLP-Ba on αSN fibrillation/cytotoxicity is attributed to a combination of free baicalein and empty NLPs. The results indicate a neuroprotective role for NLP-Ba in decreasing αSN pathogenicity in PD and highlight the use of nanoliposomes to mobilize poorly soluble hydrophobic drugs.
AB - Nanoparticles are useful for increasing drug stability, solubility, and availability. The small molecule baicalein inhibits fibrillation, and detoxifies aggregates of α-synuclein (αSN) associated with Parkinson's disease (PD), but it suffers from instability, low solubility and consequent low availability. Here it is demonstrated that incorporation of baicalein into zwitterionic nanoliposomes (NLP-Ba) addresses these problems. NLP-Ba inhibits αSN fibril initiation, elongation, secondary nucleation, and also depolymerizes mature fibrils more effectively than free baicalein and prevents soluble αSN aggregates from seeding new fibrils. Importantly, NLP-Ba perturbs oligomers’ capacity to permeabilize the membrane. The interaction between NLP-Ba and αSN is confirmed by different biophysical techniques. This nanosystem crosses the blood-brain barrier in vitro and is effective against rotenone neurotoxicity in vivo. The effect of NLP-Ba on αSN fibrillation/cytotoxicity is attributed to a combination of free baicalein and empty NLPs. The results indicate a neuroprotective role for NLP-Ba in decreasing αSN pathogenicity in PD and highlight the use of nanoliposomes to mobilize poorly soluble hydrophobic drugs.
KW - baicalein
KW - fibrillation
KW - neurotoxicity
KW - Parkinson's disease
KW - zwitterionic nanoliposomes
KW - α-synuclein
UR - http://www.scopus.com/inward/record.url?scp=85096803173&partnerID=8YFLogxK
U2 - 10.1002/adfm.202007765
DO - 10.1002/adfm.202007765
M3 - Journal article
AN - SCOPUS:85096803173
SN - 1616-301X
VL - 31
JO - Advanced Functional Materials
JF - Advanced Functional Materials
IS - 7
M1 - 2007765
ER -